Systematic screening for pharmacokinetic interactions during drug development

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 4, 1996, Pages 139-151

  Fuhr, U ^a,g   Weiss, M ^b   Kroemer, H K ^c   Neugebauer, G ^d   Rameis, H ^e   Weber, W ^f   Woodcock, B C ^g  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e Department Clinical Research ^*  (Austria)

^f SANOFI   (France)

^g UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Interaction mechanisms; Pharmacoepidemiological screening; Pharmacokinetic drug interactions

Indexed keywords

ADIPIODONE; ANTICOAGULANT AGENT; BENZODIAZEPINE; CELIPROLOL; CIMETIDINE; CLOFIBRATE; DIGOXIN; ENZYME INHIBITOR; ETACRYNIC ACID; FUROSEMIDE; GLIBENCLAMIDE; LIDOCAINE; METHYLXANTHINE; ORAL CONTRACEPTIVE AGENT; PENICILLIN G; PHENAZONE; PHENYLBUTAZONE; PHENYTOIN; PROPRANOLOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAPHENAZOLE; THEOPHYLLINE; TOLBUTAMIDE; VALPROIC ACID; VASODILATOR AGENT; WARFARIN;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INFORMATION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOEPIDEMIOLOGY;

EID: 0029876042     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Aarons L 1992 Population pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 30: 520-522
2. Altmayer P. Büch U, Hutschenreuter K, Büch HP 1987 The volatile anesthetics, halothane, enflurane and isoflurane, influence the distribution of thiopental in man differently. Acta Anaesthesiol Scand 31: 756-761
3. Ammon HPT 1991 Arzneimittelneben- und -Wechselwirkungen. Wissenschaftliche Verlagsgesellschaft, Stuttgart
4. Avagina P, Sansoè G, Martini M, Peretti P, Tinivella M, Molino G 1993 Effects of nifedipine on functional liver plasma flow in normal subjects and in patients with cirrhosis. Clin Pharmacol Ther 53: 368-373
5. Ball SE, Scatina JA, Sisenwine SF, Fisher GL 1995 The application of in vitro methods of drug metabolism and toxicity in drug discovery and drug development. Drug Chem Toxicol 18: 1-28
6. Bauer LA, Murray K, Horn JR, Opheim K, Olsen J 1989 Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. Eur J Clin Pharmacol 37: 257-260
7. Bauer LA, Stenwall M, Horn JR, Davis R, Opheim K, Greene L 1986 Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin Pharmacol Ther 40: 239-242
8. Bengtsson-Hasselgren B,.Rönn O, Blychert LO, Edgar B, Raner S 1990 Acute effects of felodipine and nifedipine on hepatic and forearm blood flow in healthy men. Eur J Clin Pharmacol 38: 529-533
9. Benowitz N, Forsyth RP, Melmon KL, Rowland M 1974 Lidocaine disposition kinetics in monkey and man. II. Effects of hemorrhage and sympathomimetic drug administration. Clin Pharmacol Ther 16: 99-109
10. Birkett DJ, MacKenzie PI, Veronese ME, Miners JO 1993 In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14: 292-294
11. Brandie E, Greven J 1992 Transport of cimetidine across the basolateral membrane of rabbit kidney proximal tubules: Interaction with organic anions. Pharmacology 45: 231-240
12. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S 1993 Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
13. Brown GR 1993 Cephalosporin-probenecid interactions. Clin Pharmacokinet 24: 289-300
14. Chelfy JE, Hysing ES, Abernethy DR, Doursout MF, Merin RG 1986 Effect of inhalational anesthetics on verapamil pharmacokinetics in dogs. Anesthesiol 65: 266-271
15. Chiu S-HL 1993 The use of in vitro metabolism studies in the understanding of new drugs. J Pharmacol Toxicol Meth 29: 77-83
16. Christensen LK, Hansen JM, Kristensen M 1963 Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics. Lancet II: 1298-1301
17. Correia MA 1995 Rat and human liver cytochromes P450. Substrate and inhibitor specificities and functional markers. In: Ortiz de Montellano PR (ed) Cytochrome P450. Structure, mechanism, and biochemistry. Plenum Press, New York, pp 607-630
18. Daneshmend TK, Jackson L, Roberts CJ 1981 Physiological and pharmacological variability in estimated hepatic blood flow. Br J Clin Pharmacol 11: 491-496
19. Day RO, Paull LP, Lam S, Swanson BR, Williams KM, Wade DN 1988 The effect of concurrent aspirin on plasma concentrations of tenoxicam. Br J Clin Pharmacol 26: 455-482
20. De Miranda P, Good SS, Yarchoan R, Thomas RV, Blum MR, Myers CE, Broder S 1989 Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 46:494-500
21. Duursema L, Müller FO, Hundt HKL, du Heyns A, Meyer BH, Luus HG 1992 Model to detect warfarin drug interactions in man. Drug Invest 4: 395-402
22. Eiermann B, Sommer N, Winne D, Schumm F, Breyer-Pfaff U 1993 Renal tubular secretion of pyridostigmine and its alteration by ranitidine and pirenzipine comedication. Arch Pharmacol 347 (Suppl): R29
23. Engel G, Knebel NG, Hofmann U, Eichelbaum M 1992 In vitro characterization of human cytochrome P450-enzymes involved in antipyrine metabolism. Abstracts of the 23rd European Workshop on Drug Metabolism (September 21-25, Bergamo)
24. Feely J, Wilkinson GR, McAllister CB, Wood AJ 1982 Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med 96: 592-594
25. Feely J 1984 Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects. Br J Clin Pharmacol 17: 83-85
26. Fichtl B, von Nieciecki A, Walter K 1991 Tissue binding versus plasma binding of drugs: General principles and pharmacokinetic consequences. Adv Drug Res 20: 117-166
27. Fraser DG, Lodden TM, Evans RP, Sutherland EW 1980 Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 27: 165-169
28. Fuhr U, Doehmer J, Battula N, Wölfel C, Kudla C, Keita Y, Staib AH 1992a Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 43: 225-235
29. Fuhr U, Anders E-M, Mahr G, Sorget F, Staib AH 1992b Inhibitory potency of quinolone antibacterial agents on cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36: 942-948
30. Fuhr U, Strebl G, Manaut F, Anders EM, Sörgel F, Lopez-de-Brinas E, Chu DTW, Pernet AG, Mahr G, Sanz F, Staib AH 1993 Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 43: 191-199
31. Fuhr U, Staib AH, Harder S, Becker K, Liermann D, Schöllnhammer G, Roed IS 1994 Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol 38: 83-86
32. George C, Fenyvesi T, Conolly ME, Dollery CT 1972 Pharmacokinetics of dextro-, laevo- and racemic propranolol in man. Eur J Clin Pharmacol 4: 74-76
33. Goldtstein JA, de Marais SMF 1994 Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299
34. Gramatté T, El Desoky E, Klotz V 1994 Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 46: 253-259
35. Grant DM, Blum M, Meyer UA 1992 Polymorphisms of N-acetyltransferase genes. Xenobiotica 22:1073-1081
36. Grasela TH, Antal EJ, Ereshefsky L, Wells BG, Evans RL, Smith RB 1987 An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther 42:433-441
37. Guengerich FP, Shimada T 1991 Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4: 391-407
38. Harder S 1991 Verapamil: A promising agent for circumvention of multi-drug resistance. Onkologie 14: 212-217
39. Henthom TK, Krejcie TC, Avram MJ 1992 The relationship between alfentanil distribution kinetics and cardiac output. Clin Pharmacol Ther 52: 190-196
40. Hirschfeld S, Jarosinski P 1993 Drug interaction of terfenadine and carbamazepine. Ann Intern Med 118: 907-908
41. Hori R, Okumura K, Inui KI, Yasuhara M, Yamada K, Sakurai T, Kawai C 1984 Quinidine-induced raise in ajmaline plasma concentrations. J Pharm Pharmacol 36: 202-204
42. Houston JB 1994 Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: 1469-1479
43. Hu OYP, Chu KM, Lin HS, Chiao SF, Ho W, Ho ST 1993 Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. Acta Anaesthesiol Scand 37: 258-261
44. Kanstrup IL, Winkler K 1987 Indocyanine green plasma clearance as a measure of changes in hepatic blood flow. Clin Physiol 7:51-54
45. Karlsson J, Kuo SM, Ziemniak J, Artursson P 1993 Transport of celiprolol across human intestinal epithelial (CaCo-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110: 1009-1016
46. Kroemer HK, Echizen H, Heidemann H, Eichelbaum M 1992 Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 260: 1052-1057
47. Kroemer HK, Klotz U 1992 Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 23: 292-310
48. Lai ML, Huang JD 1993 Dual effect of valproic acid on the pharmacokinetics of phenytoin. Biopharm Drug Dispos 14: 365-370
49. Leemann T, Transon C, Dayer P 1993 Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52: 29-34
50. Lin JH, Chen JW, Deluna FA, Hichens M 1992 Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 20: 608-613
51. McInnes GT, Brodie MJ 1988 Drug interactions that matter. A critical reappraisal. Drugs 36: 83-110
52. McKichan JJ 1984 Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet 9 (Suppl 1): 32-41
53. McKichan JJ 1989 Protein binding drug displacement interactions: Fact or fiction? Clin Pharmacokinet 16: 65-73
54. Menke G, Wörner W, Kratzer W, Rietbrock N 1989 Kinetics of drug binding to human serum albumin: allosteric and competitive inhibition at the benzodiazepine binding site by free fatty acids of various chain lengths. Arch Pharmacol 339:42-47
55. Mordel A, Halkin H, Zulty L, Almog S, Ezra D 1993 Quninidine enhances digitalis toxicity at therapeutic serum digoxin levels. Clin Pharmacol Ther 53: 457-462
56. Morgan DJ, Smallwood RA 1990 Clinical significance of pharmacokinetic models of hepatic elimination. Clin Pharmacokinet 18:61-76
57. Noormohamed FH, McNabb WR, Lant AF 1990 Pharmacokinetic and pharmacodynamic actions of enalapril in humans: Effect of probenecid pretreatment. J Pharmacol Exp Ther 253: 362-368
58. Ochs HR, Carstens G, Greenblatt DJ 1980 Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 303: 373-377
59. Oesch F, Oesch-Bartlomowicz B, Arens J, Fähndrich F, Vogel E, Friedberg T, Glatt H 1994 Mechanism-based predictions of interactions. Environ Health Perspect 102 (Suppl 9): 5-9
60. Onrot J, Shaheen O, Biaggioni I, Goldberg MR, Feely J, Wilkinson GK, Hollister AS, Robenson D 1986 Reduction of liver plasma flow by caffeine and theophylline. Clin Pharmacol Ther 40: 506-510
61. Oosterhuis B, Jonkman JHG 1993 Pharmacokinetic studies in healthy volunteers in the context of in vitro/in vivo correlations. Eur J Drug Metab Pharmacokin 18: 19-30
62. Pasanisi F, Elliott HL, Meredith PA, McSharry DR, Reid JL 1984 Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects. Clin Pharmacol Ther 36: 716-723
63. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Pedersen KK 1982 The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol 22: 123-127
64. Prittiaho HI, Sotaniemi EA, Pelkonen RO, Pitkänen U, Anttila M, Sundqvist H 1980 Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol. Br J Clin Pharmacol 9: 399-397
65. Poulsen LL, Ziegler DM 1995 Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity. Chem Biol Interact 96: 57-73
66. Rameis H, Pötzi R, Kutscher R 1991 Zur gastrointestinalen Absorption von Theophyllin insbesondere im Hinblick auf Retardpräparate. Z Gastroenterol 29: 1-5
67. Rietbrock N, Kuhlmann J, Leopold G 1983 Wechselwirkungen bei der Resorption von Arzneimitteln. Inn Med 10: 112-120
68. Rodrigues AD 1994 Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem Pharmacol 48: 2147-2156
69. Rolan PE 1994 Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 37: 125-128
70. 13C-(N-3-methyl)-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52: 170-180
71. Rowland M 1984 Protein binding and drug clearance. Clin Pharmacokinet 9 (Suppl 1): 10-17
72. Seglers EM 1984 Drug displacement interactions: a case study of the phenylbutazone-warfarin interaction. In: Reidenberg M (ed) Drug protein binding. Praeger, New York, pp 257-273
73. Shepherd AN, Hayes PC, Jacyna M, Morrison L, Bouchier IAD 1985 The influence of captopril, the nitrates and propranolol on apparent liver blood now. Br J Clin Pharmacol 19: 393-397
74. Sörgel F, Kinzig M 1993 Pharmacokinetics of gyrase inhibitors, part I: Basic chemistry and gastrointestinal disposition. Am J Med 94 (Suppl 3A): 44S-55S
75. Staib AH, Fuhr U, Raab E, Braun W, Hauk C, Chojnowski M 1991 Doxofylline/amoxycillin: Investigations on pharmacokinetics and mutual interaction in healthy volunteers. Arch Pharmacol 343 (Suppl): R87
76. Staib AH, Huschka C, Lehmann K, Petereit HU, Zaigler M, Fuhr U 1994 Tablets with pH dependent dissolving coating as a tool to investigate local drug absorption in the gut. Eur J Clin Pharmacol 47: 116
77. Staib AH, Fuhr U 1995 Drug absorption differences along the gastrointestinal tract in man: Detection and relevance for the development of new drug formulations. In: Kuhlmann J, Weihrauch TR (eds) Food-drug interactions. Clinical Pharmacology (Vol 12). Zuckschwerdt, München, pp 34-56
78. Steinijans VW, Hartmann M, Huber R. Radtke HW 1991 Lack of pharma-cokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29: 323-328
79. Suren A, Bauer FE, Rosenkranz B, Bircher J 1991 Effect of pentoxifylline on liver plasma flow in normal man. Eur J Clin Pharmacol 41: 233-237
80. Svensson CK, Cumella JC, Tronolone M, Middleton E, Lalka D 1985 Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. Clin Pharmacol Ther 37: 464-468
81. Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA 1986 Toxic interaction between acetazolamide and salicylate case reports and a pharmacokinetic explanation. Clin Pharmacol Ther 40:518-524
82. Tam YK 1993 Individual variation in first-pass metabolism. Clin Pharmacokinet 25: 300-328
83. Tanigawara Y, Okamum N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R 1992 Transport of digoxin by p-glycoprotein expressed in a porcine kidney epithelial cell line. J Pharmacol Exp Ther 263: 840-845
84. Tarbit MH, Bayliss MK, Herriot D, Hood SR, Hutson JL, Park GR, Serabjit-Singh CJ 1993 Applications of molecular biology and in vitro technology to drug metabolism studies: an industrial perspective. Biochem Soc Transact 21: 1018-1023
85. Tfelt-Hansen P, Kanstrup IL, Christensen NJ, Winkle r K 1983 General and regional haemodynamic effects of intravenous ergotamine in man. Clin Sci 65: 599-604
86. Tillement JP, Houin G, Zini R, Urien S, Albengres E, Barre J, Lecomte M, D'Athis P, Sebille B 1984 The binding of drugs to biological macromolecules in plasma. Recent advances and therapeutic significance. Adv Drug Res 13: 59-94
87. Tucker GT 1992 The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30: 550-553
88. Van Acker BA, Koomen GC, Koopman MG, de Waart DR, Arisz L 1992 Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 340: 1326-1329
89. Van Crugten J, Bochner F, Keal J, Somogyi A 1986 Selectivity of cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 236: 481-487
90. Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI 1994 In vitro prediction of the terfenadine - ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34: 1222-1227
91. Vore M 1994 Phase III elimination: Another two-edged sword. Environ Health Perspect 102: 422-423
92. Weber W, Harnisch L 1994 The population approach: An alternative strategy in detecting drug interactions. In: Kuhlmann J (ed) Drug interaction studies during drug development. Clinical Pharmacology (Vol. 11). Zuckschwerdt, München, pp 61-68
93. Welling PC 1984 Interactions affecting drug absorption. Clin Pharmacokinet 9: 404-434
94. Wong LTY, Smyth DD, Sitar DS 1992 Stereoselective inhibition of renal organic cation transport in human kidney. Br J Clin Pharmacol 34: 23-40
95. Wood M 1991 Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 21: 285-307
96. Woodcock BG, Abdel-Rahman MS, Harder S, Ganser A 1993 Kumulation von Vincristin bei intakten Zellen und ihre Modulation durch Verapamil und alpha-1-Glykoprotein. Klin Pharmakol Akt 2: 21
97. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR 1993 In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 25: 453-484
98. ZaiglerM, Fuhr U 1994 In vivo vs. in vitro comparison of inhibitory drug effects on the human cytochrome P450 isoform CYP1A2. Eur J Clin Pharmacol 47: 120